newdrugapprovals.org
Idelalisib ….US FDA Accepts NDA for Gilead’s Idelalisib for the Treatment of Refractory Indolent Non-Hodgkin’s Lymphoma
Idelalisib An antineoplastic agent and p110delta inhibitor (S)-2-(1-(9H-purin-6-ylamino)propyl)-5-fluoro-3-phenylquinazolin-4(3H)-one Icos (Originator) CAL-101 GS-1101 Idelalisib UNII-YG57I8T5M0 M.…